Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial

Vaccine

Volumn 31, Issue 40, 2013, Pages 4389-4397

  Yang, William H ^a   Dionne, Marc ^b   Kyle, Michael ^c   Aggarwal, Naresh ^d   Li, Ping ^e   Madariaga, Miguel ^e   Godeaux, Olivier ^e   Vaughn, David W ^e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c RADIANT RESEARCH   (United States)

^d Aggarwal and Associates Ltd   (Canada)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Adjuvant; H1N1; Influenza; Pandemic; Vaccine

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADULT; AGED; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FATIGUE; FEMALE; FEVER; GERIATRIC DISORDER; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROCONVERSION; SHIVERING; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; VIRION; VIRUS LOAD;

ACCORDING TO PROTOCOL; ADJUVANT; ATP; BARDA; BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY; BMI; BODY MASS INDEX; CBER; CENTER FOR BIOLOGICS EVALUATION & RESEARCH; CHMP; CI; COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE; CONFIDENCE INTERVAL; GEOMETRIC MEAN FOLD RISE; GEOMETRIC MEAN TITER; GMFR; GMT; H1N1; HA; HEMAGGLUTINATION INHIBITION; HEMAGGLUTININ; HHS; HI; ILIS; INFLUENZA; INFLUENZA-LIKE-ILLNESSES; PANDEMIC; PIMDS; POTENTIAL IMMUNE MEDIATED DISEASES; RESPIRATORY VIRAL PANEL; RVP; SAES; SCR; SD; SERIOUS ADVERSE EVENTS; SEROCONVERSION RATE; SEROPROTECTION RATE; SPR; STANDARD DEVIATION; TOTAL VACCINATED COHORT; TVC; UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES; VACCINE; VACCINE EFFECTIVENESS IMPROVEMENT; VEI; WHO; WORLD HEALTH ORGANIZATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DRUG COMBINATIONS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; POLYSORBATES; SQUALENE; VACCINATION; YOUNG ADULT;

EID: 84882817110     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.007     Document Type: Article

References (49)

1. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of influenza A(H1N1) 2009 monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.
2. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
3. Vajo Z., Tamas F., Sinka L., Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-2010 influenza season: a multicentre, randomised controlled trial. Lancet 2010, 375:49-55.
4. Madhun A.S., Akselsen P.E., Sjursen H., Pedersen G., Svindland S., Nøstbakken J.K., et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 2011, 29:266-273.
5. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Novel Swine-Origin Influenza A(H1N1). Emergence of a novel swine-origin influenza A(H1N1) virus in humans. N Engl J Med 2009, 360:2605-2615. Virus Investigation Team, [erratum in: N Engl J Med 2009;361(1):102].
6. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
7. Katz J., Hancock K., Veguilla V., Zhong W., Lu X.H., Sun H., et al. Serum cross-reactive antibody response to a novel influenza A(H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009, 58:521-524.
8. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361:1945-1952.
9. World Health Organization (WHO). Global Alert and Response (GAR). Pandemic influenza A(H1N1) 2009 virus vaccine - conclusions and recommendations from the October 2009 meeting of the immunization Strategic Advisory Group of Experts, ; December 04, 2009 [accessed 16.11.11]. http://www.who.int/csr/disease/swineflu/meetings/sage_oct_2009/en/.
10. World Health Organization (WHO), WHO recommendations on pandemic (H1N1) 2009 vaccines. Pandemic (H1N1) 2009: briefing note 2, ; July 13, 2009 [accessed 16.11.11]. http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090713/en/index.html.
11. Jackson L.A., Chen W.H., Stapleton J.T., Dekker C.L., Wald A., Brady R.C., et al. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 Adjuvant System in healthy adults and older persons. J Infect Dis 2012, 206:811-820.
12. Morel S., Didierlaurent A., Bourquiqon P., Delhaye S., Baras B., Jacob V., et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29:2461-2473.
13. Garcon N., Vaughn D.W., Didierlaurent A.M. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012, 11:349-366.
14. A-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009, 27:7428-7435.
15. Nagai H., Ikematsu H., Tenjinbaru K., Maeda A., Dramé M., Roman F.P. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults. BMC Infect Dis 2010, 10:338.
16. Leroux-Roels I., Bernhard R., Gérard P., Dramé M., Hanon E., Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008, 3:e1665.
17. Roman F., Vaman T., Gerlach B., Markendorf A., Gillard P., Devaster J.M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03(A)-trial. Adjuvant: preliminary report of an observer-blind, randomized controlled trial. Vaccine 2010, 28:1740-1745.
18. Roman F., Clement F., Dewe W., Walravens K., Maes C., Willekens J., et al. Effect on cellular and humoral immune responses of the AS03 Adjuvant System in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011, 18:835-843.
19. A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum Vaccin 2010, 6:888-893.
20. WHO Expert Committee on Biological Standardization: 56th report, Geneva, World Health Organization. Annex 5: WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines, ; 2007 [accessed 19.04.13]. http://www.who.int/biologicals/publications/trs/areas/vaccines/influenza/Annex%205%20human%20pandemic%20influenza.pdf.
21. US Food and Drug Administration (FDA) for Industry, Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration, ; May 2007 [accessed 16.11.10]. http://www.fda.gov/cber/gdlns/panfluvac.htm.
22. European Committee for Proprietary Medicinal Products (CHMP), Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products, January 24, 2007.
23. Hehme N.W., Künzel W., Petschke F., Gisela T., Carmen R., Christian van H., et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002, 22:751-769.
24. Vesikari T., Beran J., Durviaux S., Stainier I., El Idrissi M., Walravens K., et al. Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial. J Clin Virol 2012, 53:22-28.
25. Pabbaraju K., Wong S., Tokaryk K.L., Fonseca K., Drews S.J. Comparison of the Luminex xTAG Respiratory Viral Panel with xTAG Respiratory Viral Panel Fast for diagnosis of respiratory virus infections. J Clin Microbiol 2011, 49:1738-1744.
26. Gadsby N.J., Hardie A., Claas E.C.J., Templeton K.E. Comparison of the Luminex Respiratory Virus Panel Fast Assay with In-House Real-Time PCR for respiratory viral infection diagnosis. J Clin Microbiol 2010, 48:2213-2216.
27. Mahmud S., Hammond G., Elliott L., Hilderman T., Kurbis C., Caetano P., et al. Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: population-based case-control study. Vaccine 2011, 29:7975-7981.
28. Skowronski D.M., de Serres G., Crowcroft N.S., Janjua N.Z., Boulianne N., Hottes T.S., et al. Association between the 2008 and 2009 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada. PLoS Med 2010, 7:e1000258.
29. van Buynder P.G., Dhaliwal J.K., van Buynder J.L., Couturier C., Minville-Leblanc M., Garceau R., et al. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respi Viruses 2010, 4:171-178.
30. Andrews N., Waight P., Yung C.F., Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 2011, 203:32-39.
31. A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. Hum Vaccin Immunother 2012, 8:1119-1125.
32. Ferguson M., Risi G., Davis M., Sheldon E., Baron M., Li P., et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012, 205:733-744.
33. A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults. Hum Vaccin Immunother 2012, 8:1-7.
34. A-adjuvanted 2009 influenza A(H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011, 11:91-101.
35. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 Influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303:37-46.
36. Nolan T., Richmond P.C., Formica N.T., Höschler K., Skeljo M.V., Stoney T., et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus infl uenza A (H5N1) vaccine in infants and children. Vaccine 2008, 26:6383-6391.
37. Andrews N.J., Walker W.T., Finn A., et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and nonadjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. Vaccine 2011, 29:7913-7919.
38. Ohfuji S., Fukushima W., Deguchi M., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination. J Infect Dis 2011, 203:1301-1308.
39. Ohmit S.E., Petrie J.G., Malosh R.E., Cowling B.J., Thompson M.G., Shay D.K., Monto A.S. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 2013, [Epub ahead of print].
40. McElhaney J.E., Beran J., Devaster J.M., Esen M., Launay O., Leroux-Roels G., et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013, [Epub ahead of print].
41. Mahmud S.M., van Caeseele P., Hammond G., Kurbis C., Hilderman T., Elliott L. No association between 2008 and 2009 influenza vaccine and influenza A(H1N1)pdm09 virus infection, Manitoba, Canada, 2009. Emerg Infect Dis 2012, 18:801-810.
42. Talbot H.K., Coleman L.A., Crimin K., Zhu Y., Rock M.T., Meece J., et al. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine 2012, 30:3937-3943.
43. Sheridan P.A., Paich H.A., Handy J., Karlsson E.A., Hudgens M.G., Sammon A.B., et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obesity (Lond) 2011, 1-6. [Epub].
44. Saitoh A., Tamura S., Nagai A., Tsuchida N., Sako M., Maekawa T., et al. Clinical evaluation of an AS03-adjuvanted pandemic influenza H1N1 2009 vaccine in children (preliminary report). J Jap Pediatr Soc 2011, 115:578-584. [Japanese].
45. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., Stephenson I. Trial of 2009 influenza A(H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.
46. Wu J., Li W., Wang H.Q., Chen J.T., Lv M., Zhou J.C., et al. A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial. J Infect Dis 2010, 202:675-680.
47. McElhaney J.E., Zhou X., Talbot H.K., Soethout E., Bleackley R.C., Granville D.J., et al. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 2012, 30:2060-2067.
48. Talbot H.K.B., Libster R., Edwards K.M. Influenza vaccination for older adults. Human Vaccin Immunother 2012, 8:1-6.
49. van Damme P., Kafeja F., Bambure V., Hanon E., Moris P., Roman F., et al. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older. Hum Vaccin Immunother 2013, 9. [Epub ahead of print].